Table 1 Patient characteristics

From: Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)

 

GEM

GEM+CI 5-FU

Characteristics

No.

(%)

No.

(%)

Enrolled

49

 

45

 

Evaluable

48

98

43

96

Median age (years) (range)

64 (34–75)

 

62 (44–75)

 

 Gender

Male

23

48

27

63

Female

25

52

16

37

PS (Karnofsky)

 ⩾80

33

69

29

67

 <80

15

31

14

33

Previous surgery

 Yes

21

44

17

40

 No

27

56

26

60

Site of disease

 Pancreas alone

13

27

14

33

 Pancreas+liver

28

58

20

47

 Pancreas+nodes

6

13

6

14

 Others

1

1

3

7

Disease at presentation

 Locally advanced

13

27

14

33

 Metastatic disease

35

73

29

67

  1. GEM=gemcitabine; CI=continuous infusion; 5-FU=5-fluorouracil; PS=performance status.
Back to article page